Observational studyInfection2016
Factors influencing antimicrobial resistance and outcome of Gram-negative bloodstream infections in children.
Observational study in Infection, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.
- Contemporary Trends in Global Mortality of Sepsis Among Young Infants Less Than 90 Days: A Systematic Review and Meta-Analysis.Frontiers in pediatrics · 2022Pooled it
- Risk Factors and Outcomes of Extensively Drug-Resistant Gram-Negative Bacilli in Neonates with Late-Onset Sepsis.Antibiotics (Basel, Switzerland) · 2026Article
- Rates of Multidrug-Resistant Gram-Negative Bacterial Infections in Hospitalized Non-Immunocompromised Pediatric Patients: A 9-Year Retrospective Study at a Lebanese Tertiary Medical Center.Infection and drug resistance · 2025Article
- Etiology and Antimicrobial Resistance of Culture-Positive Infections in Ugandan Infants: A Cohort Study of 7000 Neonates and Infants.Open forum infectious diseases · 2024Article
- Increased rate of multidrug-resistant gram-negative bacterial infections in hospitalized immunocompromised pediatric patients.Frontiers in cellular and infection microbiology · 2024Observational
- Ceftazidime-Avibactam as a Salvage Treatment for Severely Infected Immunosuppressed Children.Drug design, development and therapy · 2024Article
- Observational
- Bloodstream Infections Caused by Multidrug Resistant Bacteria: Clinical and Microbiological Features and Mortality.Sisli Etfal Hastanesi tip bulteni · 2023Article
- Factors associated with multidrug-resistant bacteria in healthcare-associated infections: a pediatric intensive care unit case-control study.Einstein (Sao Paulo, Brazil) · 2022Article
- Optimal Management of Complicated Infections in the Pediatric Patient: The Role and Utility of Ceftazidime/Avibactam.Infection and drug resistance · 2020Review
- Review
- Future Challenges in Pediatric and Neonatal Sepsis: Emerging Pathogens and Antimicrobial Resistance.Journal of pediatric intensive care · 2019Review
- Gut Microbiota Modulation for Multidrug-Resistant Organism Decolonization: Present and Future Perspectives.Frontiers in microbiology · 2019Review
- Article
- Epidemiology and Etiology of Invasive Bacterial Infection in Infants ≤60 Days Old Treated in Emergency Departments.The Journal of pediatrics · 2018Article
- Liver Transplantation and Gut Microbiota Profiling in a Child Colonized by a Multi-Drug ResistantInternational journal of molecular sciences · 2018Article
- Factors associated with acquisition of carbapenem-resistant Enterobacteriaceae.Revista latino-americana de enfermagem · 2017Article
- Susceptibility of Austrian Clinical Klebsiella and Enterobacter Isolates Linked to Patient-Related Data.Frontiers in microbiology · 2016Article
- State of the Globe: The Rippling Effect of Multidrug-Resistant Gram-negative Infections.Journal of global infectious diseasesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe aim of this study was to collect data about pediatric Gram-negative bloodstream infections (BSI) to determine the factors that influence multidrug resistance (MDR), clinical course and outcome of children affected by Gram-negative sepsis.
methodsIn this observational, prospective, multicenter study we collected cases of pediatric Gram-negative BSI during a 2-year period. We analyzed epidemiological, microbiological and clinical factors that associated with acquisition of MDR infections and outcome.
resultsOne-hundred and thirty-five BSI episodes were analyzed. Median age of children was 0.5 years (IQR 0.1-6.17, range 0-17 years). Predominant bacteria were Enterobacteriaceae (68.3 %), and Pseudomonas spp. (17.9 %). Multidrug resistance was detected in 45/134 cases (33.6 %), with the highest rates in Escherichia coli, Enterobacter and Pseudomonas spp. Acquisition of MDR pathogens was significantly associated with prior cephalosporin treatment, older age, admission to hemato-oncology unit, polymicrobial infections, higher rate of development of septic shock, and multiple organ failures. All-cause mortality was 17.9 %. Presence of septic shock at presentation and parenteral nutrition were associated with higher mortality. Pseudomonas spp., and Enterobacter spp. BSIs had the highest rate of mortality. Inappropriate empiric antibiotic therapy was more frequent in MDR patients, although not significantly associated with poor outcome.
conclusionRates of multidrug resistance and mortality in children with Gram-negative bloodstream infections remain high in our settings. Empiric broad-spectrum antibiotics and combination therapy could be recommended, especially in children with malignant diseases, patients admitted to the PICU, and for cases with septic shock, who have higher mortality risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.